Literature DB >> 31821128

Do prescription drug monitoring programs encourage prescription - or illicit - opioid abuse?

Devon Meadowcroft1, Brian Whitacre1.   

Abstract

BACKGROUND: Prescription drug monitoring programs (PDMPs) are tools that states can use to fight prescription opioid misuse within their jurisdiction. However, because PDMPs make prescription opioids more difficult to access, these programs may have the unintended consequence of increasing deaths related to illicit opioids.
Methods: This study uses fixed effects models to estimate how PDMP regulatory strength is associated with both prescription opioid- and heroin-related deaths between 1999 and 2016. PDMP regulatory strength is measured by creating a score using multiple correspondence analysis (MCA). Additional models replace the MCA score with a binary indicator for the presence of one particular regulation requiring physicians to access the system before writing opioid prescriptions.
Results: Results show that continuous measures of PDMP strength are not generally associated with prescription opioid- or heroin-related death rates. Yet, one model does show that PDMP scores are positively associated with the heroin-related death rate. The models using the binary mandatory access variable show a strong positive association with both prescription opioid and heroin deaths. Conclusions: This study supports the theory that more stringent state PDMPs are associated with higher rates of heroin-related deaths, potentially due to decreases in prescription opioid availability.

Entities:  

Keywords:  Prescription drug monitoring programs; fixed effects models; heroin; multiple correspondence analysis; opioid epidemic; panel data

Year:  2019        PMID: 31821128     DOI: 10.1080/08897077.2019.1695707

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  5 in total

1.  Work Environment Factors and Prevention of Opioid-Related Deaths.

Authors:  William S Shaw; Cora Roelofs; Laura Punnett
Journal:  Am J Public Health       Date:  2020-06-18       Impact factor: 9.308

2.  Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018.

Authors:  Lauren R Gorfinkel; Deborah Hasin; Andrew J Saxon; Melanie Wall; Silvia S Martins; Magdalena Cerdá; Katherine Keyes; David S Fink; Salomeh Keyhani; Charles C Maynard; Mark Olfson
Journal:  J Pain       Date:  2022-02-08       Impact factor: 5.383

3.  Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin.

Authors:  Julia Dickson-Gomez; Erika Christenson; Margaret Weeks; Carol Galletly; Jennifer Wogen; Antoinette Spector; Madelyn McDonald; Jessica Ohlrich
Journal:  Subst Abuse       Date:  2021-03-25

4.  Pain and Analgesic Utilization in Medically Underserved Areas: Five-Year Prevalence Study from the Rochester Epidemiology Project.

Authors:  Ryan S D'Souza; Jennifer Eller; Chelsey Hoffmann
Journal:  J Pain Res       Date:  2022-05-03       Impact factor: 2.832

5.  The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis.

Authors:  Julia Dickson-Gomez; Sarah Krechel; Antoinette Spector; Margaret Weeks; Jessica Ohlrich; H Danielle Green Montaque; Jianghong Li
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.